fb-pixel Skip to main content
Founder and chief scientific officer of Talaris, Suzanne Ildstad, and chief executive Scott Requadt.

Talaris completes $150 million IPO as it goes after organ-transplant drugs

Talaris Therapeutics, a biotech founded nearly 20 years ago, has gone public in the latest initial public offering in the local life sciences industry.

Moderna’s CEO says he ‘didn’t lose a minute of sleep’ over potential waiver of vaccine patents

Chief executive Stephane Bancel said there aren’t enough manufacturing sites or skilled workers in the world to rapidly ramp up the supply of messenger RNA vaccines.

Dyno raises $100 million to bring artificial intelligence to gene therapy

Cambridge-based Dyno remained in stealth mode until March 2020, then quickly made a splashy debut, inking deals with Novartis, Sarepta, and Roche.

Moderna reports first profit, says early data show vaccine is 96 percent effective in adolescents

While Moderna recorded its first-ever profitable quarter, revenues of $1.94 billion came in below Wall Street expectations.

Biogen's headquarters in Cambridge.
Drug pricing watchdog says there’s ‘insufficient’ evidence that Biogen’s Alzheimer’s medicine would help patients
In a draft report, Boston-based ICER cites conflicting data from two trials. The Cambridge biotech says it “does not accurately reflect the possible holistic value” of the experimental treatment.

Moderna’s production and lab building in Norwood.
Moderna booster shots show encouraging results against variants
The Cambridge biotech releases early study data showing the vaccine’s effect on antibody levels.

Latest Headlines in Biotech

President Biden speaking about COVID-19 vaccinations last month.

Biden administration backs waiver of intellectual property protections for COVID-19 vaccines

The Biden administration is throwing its support behind efforts to waive intellectual property protections for COVID-19 vaccines in an attempt to speed the end of the pandemic.

An electronic billboard along Route 128 in Norwood advertises open jobs at Moderna.

Moderna will double Norwood plant’s size, says Mass. workforce has grown to 1,400

The expansion comes as Moderna rapidly adds to its workforce in Massachusetts. A spokesperson said the company has about 1,400 full-time employees here,

A man walks by Pfizer headquarters in New York.

Pfizer posts $4.9 billion profit in the first quarter as vaccine strategy pays off

Once viewed as a marketing machine for blockbuster treatments such as Viagra and Lipitor, Pfizer has transformed itself into a powerhouse for delivering drugs that treat cancer, rare diseases — and vaccines.

Palestinian medics unpack Moderna COVID-19 vaccines and supplies that are designated for front-line medical workers.

Moderna to supply 500 million vaccine doses to WHO’s struggling Covax initiative

Moderna will supply a vaccination campaign backed by the World Health Organization with up to 500 million doses of its coronavirus vaccine starting late this year, a much-needed boost to a global initiative that has been plagued by stark inequity, funding shortfalls, and a severe supply crunch.

Luk Vandenberghe, scientific cofounder of Affinia Therapeutics and director of the Grousbeck Gene Therapy Center at Massachusetts Eye and Ear, and Livia Carvalho.

Waltham biotech raises $110 million for gene therapy treatments

Affinia Therapeutics, founded in 2019, is working on gene therapies to treat diseases using technology developed at Massachusetts Eye and Ear.

An aerial view of Kendall Square in Cambridge.

Another class of biotech companies are about to go public in Massachusetts

Massachusetts is about to see another class of young biotech firms take the next step and become public companies, with a flurry of filings in just the past few weeks.

Lauren Farley and her mother, Susan, march through Kendall Square on their way to Biogen during a rally on March 30 for their aunt and sister-in-law, Lisa Stockman Mauriello, who has been diagnosed with a rare and aggressive form of ALS. Her friends and supporters are beseeching Biogen to grant her compassionate use of a drug, tofersen, that could save her life.

Biogen to make experimental ALS drug available to dying patients

Biogen said it will make an experimental medicine for Lou Gehrig’s disease available to some people who are dying of the incurable illness starting in July, following months of pressure from patients who had no other treatment options.

Vials of the Moderna COVID-19 vaccine at the Recipharm plant in France.

Sanofi signs deal to help make Moderna’s COVID-19 vaccine in the US

The French pharmaceutical giant said Monday it will help manufacture up to 200 million doses of Cambridge-based Moderna’s vaccine at Sanofi’s plant in Ridgefield, N.J.